Tag: Multiple Sclerosis
Industry Payments Common Among Neurologists Prescribing MS Drugs
Nearly 80 percent of neurologists received payments; higher prescription volumes linked to higher receipt of payments
Broader Formulary Coverage Linked to Lower Odds of MS Relapse
Lower odds of relapse seen among Medicare beneficiaries in prescription drug plans, Medicare Advantage Prescription Drug plans
Increase Seen in Physician Visits ~15 Years Before MS Onset
All-cause physician visit rate ratios consistently elevated from 14 years before onset, peaking in the year before MS onset
Women With MS Less Likely Than Men to Receive Disease-Modifying Therapies
Proportion of treated women began to decline 18 months before childbirth, reaching 27.9 percent at the estimated time of conception
Greater Epigenetic Age Seen in Patients With Pediatric-Onset MS
For two of the four epigenetic clocks used, the difference in epigenetic age was significant
Neuromodulation Methods Show Comparable Outcomes for Neurogenic Bladder in Women With MS
No significant difference seen in urodynamic testing results between TPTNS and rTMS groups
AAN: Tolebrutinib Slows Disability in Nonrelapsing Secondary Progressive MS
Tolebrutinib treatment associated with 31 percent risk reduction in six-month confirmed disability progression versus placebo
Higher Fish Intake Linked to Reduced Risk for MS Disability Worsening
More pronounced protective effects seen in patients who maintained consistent fish consumption during follow-up
Early Childhood Sun Exposure Linked to Lower Risk for Pediatric MS Relapse
Greater time spent in sun during second trimester of pregnancy also linked to reduced risk for relapse in offspring with MS
Multiple Sclerosis May Worsen With Menopause Transition
Findings show accumulation of neuronal injury and functional decline
